The ruling means that small-scale compounders must immediately stop making their versions of Novo’s Ozempic and Wegovy, while ...

Eli Lilly's Orforglipron shines in Phase III trials, potentially leading diabetes and obesity treatment by 2026. See what to ...

Patients flocked to those Ozempic, Wegovy copycats when the branded drugs were in short supply, or if they didn’t have ...

One such example is Novo Nordisk (NYSE: NVO), the Denmark-based pharmaceutical leader whose shares are exchanging hands for ...

The pecking order of the obesity drug market is shifting. Eli Lilly , the $815 billion maker of blockbuster weight-loss drugs ...

April 24 - A U.S. judge on Thursday rejected a bid by compounding pharmacies to keep making copies of Novo Nordisk's popular diabetes and weight-loss drugs Ozempic and Wegovy while a legal challenge ...

A US judge on Thursday rejected a bid by compounding pharmacies to keep making copies of Novo Nordisk's popular diabetes and ...

Eli Lilly said its new weight-loss pill had cleared a late-stage clinical trial, a promising sign as the company continues to ...

Companies are announcing significant investments in U.S. manufacturing in response to looming tariffs. An AstraZeneca ...

Lexaria Bioscience (LEXX) provides a glucagon-like peptide-1 strategic update following important industry developments reported both by Pfizer ...

FDA Commissioner Marty Makary talks about his plans to revamp drug development and reduce ‘conflicts of interest’ between the ...

Pharmaceutical giant Eli Lilly alleges the companies are selling illegal off-brand versions of its best-selling diabetes and ...